Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 4/20 | 0.41 |
| ▸ | CCND1 | P24385 | 4/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | TLR8 | Q9NR97 | 3/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.35 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28246061 | 0.95 | CDK4 (0.42) | CDK4CCND1SLC6A2PTGDR2DRD2 | |
| Hexane SCHEMBL27318078 | 0.72 | CDK4 (0.46) | CDK4CCND1SLC6A2DRD2SLC6A4 | |
| SCHEMBL30495581 | 0.70 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CTLR8 | |
| SCHEMBL4554026 | 0.70 | CDK4 (0.81) | CDK4CCND1HTR2AHTR2CTLR8 | |
| SCHEMBL30416543 | 0.70 | NOTUM (0.48) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL17288078 | 0.70 | NOTUM (0.48) | CDK4CCND1HTR2AHTR2CNOTUM | |
| SCHEMBL10774534 | 0.70 | SLC6A2 (0.51) | CDK4CCND1SLC6A2SLC6A4 | |
| SCHEMBL30376 | 0.69 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CTLR8 | |
| SCHEMBL29767815 | 0.69 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CTLR8 | |
| SCHEMBL4976386 | 0.69 | CDK4 (0.82) | CDK4CCND1HTR2AHTR2CTLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2006041961-A1 | ARYLTHIOINDOLE TUBULIN POLYMERIZATION INHIBITORS AND METHODS OF TREATING OR PREVENTING CANCER USING SAME | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES (US) | 2006-04-20 | — | — | WO | claimed |
| EP-3564239-B9 | ARYL HYDROCARBON RECEPTOR MODULATOR | ARIAGEN INC (US) | 2023-04-19 | — | — | EP | disclosed |
| WO-2011121629-A1 | INDOLIC DERIVATIVES AND USE THEREOF IN MEDICAL FIELD | UNIVERSITA' DEGLI STUDI DL ROMA "LA SAPIENZA" (IT) | 2011-10-06 | — | — | WO | disclosed |
| EP-1501826-B1 | SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS | HOFFMANN LA ROCHE (CH) | 2006-09-27 | — | — | EP | disclosed |
| WO-2006041961-A1 | ARYLTHIOINDOLE TUBULIN POLYMERIZATION INHIBITORS AND METHODS OF TREATING OR PREVENTING CANCER USING SAME | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES (US) | 2006-04-20 | — | — | WO | disclosed |
| WO-2006041961-A1 | ARYLTHIOINDOLE TUBULIN POLYMERIZATION INHIBITORS AND METHODS OF TREATING OR PREVENTING CANCER USING SAME | GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTHAND HUMAN SERVICES (US) | 2006-04-20 | — | — | WO | disclosed |
| US-6852726-B2 | Substituted indoles as alpha-1 agonists | SYNTEX LLC (US) | 2005-02-08 | — | — | US | disclosed |
| EP-1501826-A2 | SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS | F. Hoffman-la Roche AG (CH) | 2005-02-02 | — | — | EP | disclosed |
| US-20030220319-A1 | Substituted indoles as alpha-1 agonists | SYNTEX (U.S.A.) LLC | 2003-11-27 | — | — | US | disclosed |
| WO-2003064387-A2 | SUBSTITUTED INDOLES AS ALPHA-1 AGONISTS | F. HOFFMAN-LA ROCHE AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220319-A1 | Substituted indoles as alpha-1 agonists | ADRA1A, ADRB1, ADRA1B | CDK4 4365/4885CCND1 1753/4885SLC6A2 326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.